Good News from the lab. The Oak Crest team demonstrate that a novel subdermal implant can safely prevent HIV in mice. The drug under study, tenofovir alafenamide (TAF), is a precursor of tenofovir used to control HIV and hepatitis B infections. In this report, TAF was released from subdermal implants and accumulated in immune cells as the active metabolite against HIV without any adverse effects. The study suggests that subdermal TAF implants used for durations of six months, or longer, merit further investigation and addresses important knowledge gaps surrounding long-acting systemic TAF delivery.
Download the paper “Fundamental aspects of long-acting tenofovir alafenamide delivery from subdermal implants for HIV prophylaxis” here